Navigating Treatment Resistance and Sequencing in CLL

The KOMET-001 trial meets its primary end point of CR/CRh rate among patients with NPM1-mutated acute myeloid leukemia.

Therapies such as betibeglogene autotemcel have been “life-changing” for patients with β-thalassemia, according to Nora M. Gibson, MD, MSCE.

Researchers demonstrated that haplo-HSCT, combined with post-transplant cyclophosphamide, is a feasible and effective treatment for hematologic malignancies even in resource-limited settings.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Phase 3 VERIFY study findings showed rusfertide maintained a manageable safety profile consistent with previous studies.

Findings support the established safety profile of lisocabtagene maraleucel across hematologic oncology indications.